{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:34:24Z","timestamp":1761237264693},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1053\/j.seminoncol.2004.07.021","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"45-50","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S10","title":["Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer"],"prefix":"10.1053","volume":"31","author":[{"given":"Pierre","family":"Fumoleau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2004.07.021_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib2","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","article-title":"Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer, relapsing after treatment with a taxane-containing therapy","volume":"14","author":"Reichardt","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","article-title":"Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer","volume":"40","author":"Fumoleau","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","article-title":"Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer","volume":"12","author":"O\u2019Shaughnessy","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib6","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer","volume":"20","author":"O\u2019Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib7","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjc.6600261","article-title":"Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic\/advanced breast cancer pretreated with anthracyclines","volume":"86","author":"Talbot","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib8","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<127::AID-IJC22>3.0.CO;2-6","article-title":"Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5\u2032-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models","volume":"83","author":"Endo","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-001-0401-7","article-title":"Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine\/5\u2032-dFUrd in human breast cancer models","volume":"49","author":"Fujimoto-Ouchi","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib11","first-page":"1013","article-title":"Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol\/Taxotere in human cancer xenografts","volume":"4","author":"Sawada","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib12","first-page":"2948","article-title":"X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts","volume":"5","author":"Sawada","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib13","first-page":"1088","article-title":"Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumour xenograft models","volume":"43","author":"Sawada","year":"2002","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib14","first-page":"508","article-title":"Combination of Avastin and Xeloda synergistically inhibits colorectal tumor growth in a Colo205 tumor xenograft model","volume":"45","author":"Shen","year":"2004","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib15","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/sj.bjc.6601784","article-title":"Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced\/metastatic breast cancer","volume":"90","author":"Batista","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib16","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.2004.12.128","article-title":"Capecitabine plus paclitaxel as front line combination therapy for metastatic breast cancer","volume":"22","author":"Gradishar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib17","first-page":"28a","article-title":"Phase III randomized trial of primary chemotherapy with doxorubicin\/ cyclophosphamide (AC) vs. docetaxel\/capecitabine (TX) for stage II\/III breast cancer (BC)","volume":"23","author":"Lee","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib18","first-page":"1161","article-title":"Coming to grips with hand-foot syndrome","volume":"18","author":"Scheithauer","year":"2004","journal-title":"Oncology (Huntingt)"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib19","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1023\/A:1008209429204","article-title":"Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer","volume":"8","author":"Nol\u00e9","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib20","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1023\/A:1008389106575","article-title":"Primary chemotherapy in operable breast cancer with favorable prognostic factors","volume":"10","author":"Nol\u00e9","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/bjc.1998.558","article-title":"Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor","volume":"78","author":"Kornek","year":"1998","journal-title":"Br J Cancer"},{"issue":"suppl 5","key":"10.1053\/j.seminoncol.2004.07.021_bib22","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/S1359-6349(03)90403-4","article-title":"In vivo-chemosensitivity adapted primary chemotherapy in patients with primary breast cancer. Results of the Gepartrio-Pilot trial","volume":"1","author":"von Minckwitz","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib23","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.3816\/CBC.2003.s.010","article-title":"Neoadjuvant chemotherapy for operable breast cancer","volume":"4","author":"Mamounas","year":"2003","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib24","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib25","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D","article-title":"Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy","volume":"62","author":"Hortobagyi","year":"1988","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib26","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","article-title":"Preoperative chemotherapy in primary operable breast cancer","volume":"19","author":"van der Hage","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib27","first-page":"34a","article-title":"First report of the European Cooperative Trial in operable breast cancer (ECTO)","volume":"21","author":"Gianni","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.1995.13.2.424","article-title":"High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer","volume":"13","author":"Smith","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1634\/theoncologist.9-2-207","article-title":"Thrombotic complications of central venous catheters in cancer patients","volume":"9","author":"Kuter","year":"2004","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib30","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/0277-9536(92)90053-S","article-title":"A study of quality of life in cancer patients receiving palliative chemotherapy","volume":"35","author":"Payne","year":"1992","journal-title":"Soc Sci Med"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib31","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1200\/JCO.2003.08.008","article-title":"Venous thromboembolism associated with long-term use of central venous catheters in cancer patients","volume":"21","author":"Verso","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0959-8049(97)89012-0","article-title":"A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy","volume":"33","author":"Nightingale","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib33","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/S0959-8049(96)00274-2","article-title":"Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy","volume":"32","author":"Poorter","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib34","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0959-8049(03)00266-1","article-title":"An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (CEX) as primary treatment for large operable or locally advanced\/inflammatory breast cancer","volume":"39","author":"Bonnefoi","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib35","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.11203","article-title":"Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma","volume":"97","author":"Venturini","year":"2003","journal-title":"Cancer"},{"issue":"suppl 6","key":"10.1053\/j.seminoncol.2004.07.021_bib36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0959-8049(01)81203-X","article-title":"Dose-finding study of docetaxel (T) and doxorubicin (A) day 1 and 8 plus capecitabine (X) day 1 to 14 (TAX) as first line treatment in advanced breast cancer (ABC)","volume":"37","author":"Pagani","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib37","first-page":"27","article-title":"Phase II study of epirubicin, cisplatin and capecitabine as neo-adjuvant chemotherapy in women with locally advanced or inflammatory breast cancer","volume":"22","author":"Ahlgren","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.07.021_bib38","first-page":"133","article-title":"Navelbine (N) capecitabine (C) combination (Navcap); the new first line chemotherapy regimen for metastatic breast cancer (MBC)","volume":"76","author":"Ghosn","year":"2002","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.07.021_bib39","first-page":"S90","article-title":"Extended phase I study of capecitabine in combination with vinorelbine in pretreated patients with advanced breast cancer","volume":"76","author":"Welt","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib40","first-page":"46a","article-title":"Vinorelbine and capecitabine (VX) for advanced breast cancer - A phase II study showing good activity and potential for further development","volume":"22","author":"Stuart","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.021_bib41","first-page":"54","article-title":"Phase II study of capecitabine and vinorelbine in anthracycline and taxane pretreated breast cancer patients","volume":"22","author":"Ahn","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 5","key":"10.1053\/j.seminoncol.2004.07.021_bib42","first-page":"56","article-title":"A phase I study of vinorelbine plus capecitabine in patients with advanced breast cancer","volume":"13","author":"Sambiasi","year":"2002","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.07.021_bib43","first-page":"S91","article-title":"Vinorelbine (VR) and capecitabine (CAP) in metastatic breast cancer","volume":"76","author":"Schott","year":"2002","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 2","key":"10.1053\/j.seminoncol.2004.07.021_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1359-6349(04)90881-6","article-title":"Dose-finding study of the combination of oral idarubicin and oral capecitabine in the treatment of locally advanced or advanced breast cancer","volume":"3","author":"Nussey","year":"2004","journal-title":"Eur J Cancer"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404003689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404003689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:35:08Z","timestamp":1554338108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775404003689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":44,"alternative-id":["S0093775404003689"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2004.07.021","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}